* International expertise to lead SAIK-MS effect studies (Phase II)

* Permission to start TTS Phase II trials in the UK expected shortly (renal cancer)

* Progress in the cooperation with the Johns Hopkins University in the US on prostate cancer - substance shows a significant anti-tumour effect in experimental models

* Capital gains on the sale of SBL Vaccin amounted to SEK 342 million

* Profit after financial items for the period reached SEK 279.8 million (SEK -32.7 m)